Compare INTT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | QNCX |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 167.0M |
| IPO Year | 1997 | 2019 |
| Metric | INTT | QNCX |
|---|---|---|
| Price | $14.40 | $0.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.50 | $10.00 |
| AVG Volume (30 Days) | 145.8K | ★ 16.6M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $5.24 | $0.08 |
| 52 Week High | $15.01 | $4.55 |
| Indicator | INTT | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 71.87 | 28.47 |
| Support Level | $7.21 | $0.09 |
| Resistance Level | $15.01 | $0.98 |
| Average True Range (ATR) | 0.90 | 0.01 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 80.45 | 28.17 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.